This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This pharmaphorum webinar, held in association with Savana, will take place on Thursday 22 April from 16:00-17:00 BST / 17:00-18:00 CET / 10:00-11:00 EST and hear from presenters at BREATHE – the health dataresearch hub for respiratory health, Salford Royal NHS Foundation Trust and Savana.
We know that the demand at the site level for studies is growing and the workforce capacity is shrinking, notes Bree Burks, RN, MSN, Vice President of Strategy for Veeva Systems, who will present on The ClinicalResearch Technology Reboot: Are We Getting it Right? The ClinicalResearch Technology Reboot: Are We Getting it Right?
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Through these collaborations, advanced technologies tied to AI and bigdata are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.
With this, we can elevate and simplify the clinical trial experience for research professionals and participants. More accurate data. Data collected via mobile app is arguably cleaner and more objective than traditional methods in clinicalresearch. Power behind BigData.
It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements. “Access to raw data can assist regulators in understanding the submitted evidence and therefore inform the regulatory decisions on the benefit-risk balance of the product,” it continues.
Time is also of the essence in drug development, as competitive product-to-market lead times help pharma companies improve profitability. Time spent on clinical trials involves investment and being able to predict ADRs assists with improving the success rate. Navro Technology Solutions – AI-Based Pharmacovigilance.
As an ‘agency’ that generates insights services that bridge the relationships between patients and industry, we are in a unique position to ensure these practices are ethical and productive – ultimately delivering improved outcomes for patients, pharma and society. Rise of the machines – bigdata, AI and machine learning.
As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.
Although approach differs slightly amongst organizations in clinicalresearch, everyone agrees on this: it’s time for the industry to become more agile. Too many life-saving treatments and medical advancements are at stake to remain attached to the traditional ways of data collection.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content